Get the Stockscreener App
131.87
0.54%
-0.72
After Hours:
131.87
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $131.87, with a volume of 3.57M.
It is down -0.54% in the last 24 hours and up +4.21% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$132.59
Open:
$132.72
24h Volume:
3.57M
Relative Volume:
0.55
Market Cap:
$229.51B
Revenue:
$43.11B
Net Income/Loss:
$13.94B
P/E Ratio:
16.53
EPS:
7.98
Net Cash Flow:
$6.78B
1W Performance:
+1.23%
1M Performance:
+4.21%
6M Performance:
-2.91%
1Y Performance:
+17.02%
1-Day Range:
$131.49
$132.96
1-Week Range:
$128.68
$133.81
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
131.87 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
105.11 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
390.88 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.02 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
80.88 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Top Research Reports for Amazon.com, Salesforce & Abbott - MSN
Abbott Sues Chinese Rival Over Glucose Monitor UK Patent - Law360
Abbott Gets $7 Million Shaved From Tax Value of Minnesota Lab - news.bloombergtax.com
Should You Invest in Abbott (ABT) Based on Bullish Wall Street Views? - Yahoo Finance
Abbott gets 2nd formula lawsuit dismissed, spelling trouble for 700 cases - Crain's Chicago Business
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Stock Analysis | Abbott Laboratories OutlookMixed Signals Amid Fundamental Strength - AInvest
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Alcohol assay from Carolina Liquid Chemistries receives CLIA moderate complexity categorization on Abbott ImmTox™ 270 chemistry analyzer - News-Medical
1 Cash-Producing Stock for Long-Term Investors and 2 We Question - FinancialContent
Synlait mum on rumoured US buyer for 'cash burning' Pōkeno plant - ThePost.co.nz
Abbott Shares Slide 1.12% as Trading Volume Dives 43.81% to 182nd Rank Amid Blood Campaign Push - AInvest
Abbott Laboratories scores a win in federal court, as it faces hundreds of suits over formula for preterm babies - Chicago Tribune
Here's Why We Think Abbott Laboratories (NYSE:ABT) Is Well Worth Watching - 富途牛牛
$1 Million Prize: Abbott and Big Ten's Massive Blood Drive Competition Returns After 12,000 Lives Saved - Stock Titan
Abbott Gains in Nutrition With Adult Segment Leading Growth - Yahoo Finance
Abbott Laboratories (NYSE:ABT) Could Easily Take On More Debt - Yahoo Finance
Synlait to sell plant to Abbott Labs as a2 Milk buys asset from rival - The Australian
Abbott Laboratories Sheds 8% On A Rare Guidance Miss - MSN
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
What is the target price for Abbott Laboratories stockWeekly Risk Report & Growth Focused Investment Plans - thegnnews.com
Insider Sales: D-Wave, AGNC, BigBearai, Abbott, Etsy - TipRanks
2 Stocks to Buy on the Dip and Hold for 10 Years - The Motley Fool
EXPERT EVIDENCE—BABY PRODUCTS—N.D. Ill.: Expert’s testimony did not apply to preterm infant; Abbott Labs thus entitled to summary judgment in baby formula litigation - VitalLaw.com
Abbott Laboratories (NYSE:ABT) Q2 2025 Earnings Call Transcript - MSN
How Abbott Laboratories stock performs during market volatilityJuly 2025 Outlook & Reliable Price Breakout Signals - thegnnews.com
Abbott Shares Dip Despite Record Volume Surge and FDA Approval Targets 20 CAGR Market Ranks 57th in Daily Trading Activity - AInvest
Abbott Taps Growing TMVR Market With Tendyne System - The Globe and Mail
Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist? - Yahoo Finance
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT) - msn.com
Saudi Arabia Blood Glucose Device Market Trends and Company - GlobeNewswire
Saudi Arabia Blood Glucose Device Market Trends and Company Analysis Report 2025-2033 Featuring Abbott Laboratories, Medtronic, Dexcom, Braun, DarioHealth, Sanofi, Bionime, and Novo Nordisk - Yahoo Finance
Chris Blumas' Past Picks: Brookfield Corp, Abbott Labs & Great-West Lifeco - BNN Bloomberg
United States Epilepsy Drugs Market Trends and Company - GlobeNewswire
United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK - Yahoo Finance
US Personalized Medicine Market Trends and Company Analysis Report 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La Roche - Yahoo Finance
Abbott India's profit climbs on healthy pharmaceutical demand - Reuters
Top Abbott Executive Makes Significant Stock Sale! - TipRanks
Abbott Plummets 2.17% Amid Regulatory Scrutiny as Volume Surges 40.74% to 940M Ranking 93rd - AInvest
Abbott Shakes Suit Over Meta, Google Data Sharing For Now - Law360
Abbott Laboratories EVP and CFO Sells 5,550 Shares at $134.55/Share on August 8, 2023. - AInvest
Abbott Laboratories poised to end in red after six-session rally - MSN
Abbott Laboratories stock underperforms Monday when compared to competitors - MarketWatch
Abbott Laboratories Faces Correction Amid Six-Session Rally - AInvest
Abbott Labs Beats Class Action Over Meta, Google Info Sharing - Bloomberg Government News
Abbott Laboratories shows growth in core products amid market shifts - Yahoo Finance
Are Wall Street Analysts Predicting Abbott Laboratories Stock Will Climb or Sink? - Yahoo Finance
Abbott Laboratories maintains steady performance amid market shifts - Express Healthcare
Abbott Laboratories (NYSE:ABT) jumps 5.5% this week, though earnings growth is still tracking behind five-year shareholder returns - Yahoo Finance
Abbott's EPD Growth Beats Market Trends: Here's How to Play the Stock - MSN
Abbott Laboratories Q2 Earnings: Dividends Don’t Lie (NYSE:ABT) - Seeking Alpha
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):